title: Important aspects of cost-effectiveness analysis in febrile neutropenia.
authors.forename: M
authors.initials: M
authors.lastname: Karthaus
authors.forename: A
authors.initials: A
authors.lastname: Boehme
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: H
authors.initials: H
authors.lastname: Juergens
mesh_terms: D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005334:Fever / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000188:drug therapy* / Q000382:microbiology; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents